Notified in December 2023, the revised Schedule M has shifted the focus from “good manufacturing practices” to “good ...
Low compliance by the country’s 8,500 small and medium enterprises (MSMEs) manufacturing pharmaceuticals would raise the risk ...
The health ministry is unlikely to extend the Schedule M deadline for MSME pharma firms beyond December 31, 2025, as it ...
Outlook Business on MSN
Over 60% of Small Pharma Units May Face Closure over New Compliance Norms
Over 60% of India’s small and medium pharmaceutical units risk shutting down by the end of December for not meeting updated good manufacturing practice (GMP) standards.
Capital Market on MSN
Strides Pharma slides as US arm receives 4 USFDA observations for New York facility
In an exchange filing, the company said the current Good Manufacturing Practices (cGMP) inspection was conducted by the US ...
Indian Pharmaceutical Alliance (IP Alliance) is investing $15 million to set up a dedicated quality institute in Ahmedabad. This will be focused on quality parametres roping in the state and Central ...
Pharmaceutical firms must prioritize AI integration, supply resilience to thrive in 2026: Nikkhil Masurkar: Shardul Nautiyal, ...
This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility ...
Four pharma stocks to watch today as Lupin signs a peptide API deal, Dr Reddy’s and Aurobindo face FDA observations, and Biocon clears a global launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback